Which Cannabinoid Is Strongest for Pain? THC, CBD, CBG and CBN Co…

THC, or delta-9-tetrahydrocannabinol, is the strongest cannabinoid for pain. It takes the top spot on four criteria: the depth of human clinical data, direct activity at CB1 and CB2 receptors, control over onset and dose when inhaled, and the range of lab-tested products sold in US dispensaries. CBD, CBG, CBN, CBC and THCV all appear in pain-focused products, but none carries the same mix of evidence and effect size.

THC (delta-9-tetrahydrocannabinol): top pick

THC is a partial agonist at CB1 receptors in the brain and spinal cord, the system that governs pain signaling, and it also acts at CB2 receptors tied to inflammation. Trials of smoked cannabis in the 3.5% to 9% THC range, plus trials of the 1:1 THC and CBD oromucosal spray used in Canada and parts of Europe, report pain reductions in a share of patients with neuropathic and chronic pain. Inhaled flower and vapes act within minutes. Edibles and tinctures last longer but arrive later and hit harder.

THC-P Potency Explained: What the 33x Figure Means for Dose and Format

Pros: largest human evidence base of any cannabinoid; fast onset when inhaled; broad choice of ratios, potencies and dose forms in state-legal stores; CB1 activity that other cannabinoids lack.
Cons: intoxication, anxiety and racing heart at high doses; impaired driving and job performance; tolerance and dependence risk with daily use; a poor fit for some people with a personal or family history of psychosis.

Best for: moderate to severe or neuropathic pain when CBD alone has not helped, and for users who want fast relief and can manage psychoactive effects. Start near 2 mg to 5 mg and wait before redosing.

CBD (cannabidiol)

CBD does not bind CB1 with much strength. It works through other targets such as TRPV1 and 5-HT1A, and it slows the breakdown of the body's own endocannabinoids. Reviews of CBD for chronic pain show mixed results from studies of low quality, and the FDA has approved purified CBD only for certain seizure disorders, not for pain. CBD remains useful in daytime products because it does not intoxicate.

Pros: no high, so it fits work and driving; widely available as hemp-derived product; pairs well in ratios with THC; early signals for inflammatory and joint discomfort.
Cons: weak on its own against severe pain; needs high doses, often 25 mg to 100 mg or more; can raise blood levels of some prescription drugs through liver enzymes; label accuracy varies by brand.

Best for: mild pain, daytime dosing, and anyone who cannot tolerate THC. Buy from sellers who post third-party lab results for potency and contaminants.

CBG (cannabigerol)

CBG binds weakly at CB1 and CB2 and acts at alpha-2 adrenergic receptors, which are linked to pain signaling. Human trials are early and small, so most claims rest on lab and animal work. Retail products often list 5 mg to 15 mg per dose, and flower usually carries well under 1% CBG.

Pros: non-intoxicating; preliminary signals for inflammation and gut discomfort; stacks with THC or CBD in the same product.
Cons: thin human pain data; costly per milligram; often underdosed in flower, so labels overstate the effect.

Best for: adding a non-intoxicating minor cannabinoid to a THC or CBD base. Treat it as a supporting player, not a standalone answer for pain.

CBN (cannabinol)

CBN is an oxidation product of THC and forms as flower ages. Its sleep-aid reputation traces back to a small older rodent study. Its CB1 affinity is low next to THC, and human pain trials are scarce.

Pros: sedation reputation that suits night blends; mild on its own; common in THC and CBN vapes for evening use.
Cons: weak receptor activity; no solid human pain data; marketing runs ahead of the science.

Best for: nighttime products where sleep support matters more than daytime pain control. If pain wakes you, a THC-forward blend will do more work than CBN alone.

CBC and THCV

CBC acts at TRPV1 and TRPA1, two receptors involved in pain and inflammation. THCV behaves as a CB1 antagonist at low doses and a partial agonist at high doses, with most data coming from preclinical work. Both are usually sold as accents in a blend at 1 mg to 10 mg per serving.

Pros: non-intoxicating at common doses; CBC shows early anti-inflammatory signals; THCV may support appetite and focus control alongside pain relief.
Cons: minimal human pain evidence; premium pricing; effects hard to isolate from the THC or CBD they sit beside.

Best for: experienced users who read full panels and want to test minor cannabinoids alongside a proven THC or CBD base.

THC plus CBD blends

Ratio products such as 1:1, 2:1 and 5:1 pair THC's receptor activity with CBD's calming and anti-inflammatory reach. The 1:1 oromucosal spray is the most studied combination for chronic pain. CBD can soften THC's anxiety and may extend the relief window.

Pros: broader effect profile; less THC per puff, which suits new users; ratios make titration easier for some patients.
Cons: harder to predict than a single cannabinoid; effects shift with the ratio and the delivery method; not all labels match tested content.

Best for: users who want THC-level relief with a lower chance of a rough edge, and for anyone stepping up from CBD.

How to match a cannabinoid to your pain

Name the pain pattern: sharp and episodic pain responds to inhaled THC, while constant deep ache often suits longer-acting edibles or tinctures.
Start with the lowest effective THC dose, then add CBD or CBG rather than raising THC.
Track dose, time and effect for two weeks so you can tell a real change from a good day.
Check interactions with a pharmacist if you take blood thinners, seizure drugs, or sedatives.
Buy only from licensed sellers who publish batch lab tests for potency, pesticides and mold.

THC holds the top rank, with CBD as the best non-intoxicating partner and CBG, CBN, CBC and THCV as accents that need more research before they can carry a pain routine on their own.